Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control | Zendy

Andrea Calcagno | Zendy; Marco Simiele | Zendy; Maria Chiara Alberione | Zendy; Margherita Bracchi | Zendy; Letizia Marinaro | Zendy; Sara Ecclesia | Zendy; Giovanni Di Perri | Zendy; Antonio D’Avolio | Zendy; Stefano Bonora | Zendy

Open Access

Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control

Author(s) -

Andrea Calcagno,

Marco Simiele,

Maria Chiara Alberione,

Margherita Bracchi,

Letizia Marinaro,

Sara Ecclesia,

Giovanni Di Perri,

Antonio D’Avolio,

Stefano Bonora

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu773

Subject(s) - cerebrospinal fluid , medicine , darunavir , efavirenz , interquartile range , viral load , saquinavir , raltegravir , drug , immunology , pharmacokinetics , indinavir , pharmacology , gastroenterology , virology , human immunodeficiency virus (hiv) , antiretroviral therapy

Despite the efficacy of highly active antiretroviral treatment (HAART), a large proportion of human immunodeficiency virus (HIV)-infected patients may develop moderate neurocognitive impairment. Antiretroviral drug passage into the central nervous system may be relevant for preventing and treating HIV-associated neurocognitive disorder; nevertheless, clear cerebrospinal fluid (CSF) pharmacodynamic targets are not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research